1. |
Casotti V, Lorenzo D. Basic principles of liver physiology. Berlin: Springer International Publishing, 2019: 21-39.
|
2. |
de Boer Y S, Kosinski A S, Urban T J, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol, 2017, 15(1): 103-112.
|
3. |
Ramachandran P, Dobie R, Wilson-Kanamori J R, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature, 2019, 575(7783): 512-518.
|
4. |
Cole B K, Feaver R E, Wamhoff B R, et al. Non-alcoholic fatty liver disease (NAFLD) models in drug discovery. Expert Opin Drug Discov, 2018, 13(2): 193-205.
|
5. |
卢贤欢, 赵华琛, 王雪, 等. 体外肝脏 3D 模型在药物肝毒性评价中的优势. 药学学报, 2017, 52(12): 1859-1864.
|
6. |
Williamson T, Sultanpuram N, Sendi H. The role of liver microenvironment in hepatic metastasis. Clin Transl Med, 2019, 8(1): 21.
|
7. |
Utoh R, Komori J, Kuge H, et al. Adult hepatocytes direct liver organogenesis through non-parenchymal cell recruitment in the kidney. J Hepatol, 2018, 68(4): 744-753.
|
8. |
Wang M, Liu S, Xu Z, et al. Characterizing poroelasticity of biological tissues by spherical indentation: an improved theory for large relaxation. J Mech Phys Solids, 2020, 138: 103920.
|
9. |
Underhill G H, Khetani S R. Bioengineered liver models for drug testing and cell differentiation studies. Cell Mol Gastroenterol Hepatol, 2018, 5(3): 426-439.
|
10. |
Vilas-Boas V, Cooreman A, Gijbels E, et al. Primary hepatocytes and their cultures for the testing of drug-induced liver injury. Adv Pharmacol, 2019, 85: 1-30.
|
11. |
Xu J Y, Oda S, Yokoi T. Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury. Toxicol In Vitro, 2018, 48: 286-301.
|
12. |
Abdellatef S A, Ohi A, Nabatame T, et al. The effect of physical and chemical cues on hepatocellular function and morphology. Int J Mol Sci, 2014, 15(3): 4299-4317.
|
13. |
Seitz H K, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers, 2018, 4(1): 16.
|
14. |
Mahli A, Koch A, Fresse K, et al. Iso-alpha acids from hops (Humulus lupulus) inhibit hepatic steatosis, inflammation, and fibrosis. Lab Invest, 2018, 98(12): 1614-1626.
|
15. |
Lee J, Choi B, No D Y, et al. A 3D alcoholic liver disease model on a chip. Integr Biol (Camb), 2016, 8(3): 302-308.
|
16. |
Deng J, Chen Z, Zhang X, et al. A liver-chip-based alcoholic liver disease model featuring multi-non-parenchymal cells. Biomed Microdevices, 2019, 21(3): 57.
|
17. |
Huang G, Li F, Zhao X, et al. Functional and biomimetic materials for engineering of the three-dimensional cell microenvironment. Chem Rev, 2017, 117(20): 12764-12850.
|
18. |
Zhang Y, Wang C, Yu B, et al. Gastrodin protects against ethanol-induced liver injury and apoptosis in HepG2 cells and animal models of alcoholic liver disease. Biol Pharm Bull, 2018, 41(5): 670-679.
|
19. |
Choi W M, Kim M H, Jeong W I. Functions of hepatic nonparenchymal cells in alcoholic liver disease. Liver Research, 2019, 3: 80-87.
|
20. |
Kirchner V A, Tak E, Kim K, et al. The evolving microenvironment of the human hepatocyte: healthy vs. cirrhotic liver vs. isolated cells. Tissue Cell, 2020, 62: 101310.
|
21. |
Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int, 2017, 37(Suppl 1): 85-89.
|
22. |
Friedman S L, Neuschwander-Tetri B A, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med, 2018, 24(7): 908-922.
|
23. |
Kozyra M, Johansson I, Nordling Å, et al. Human hepatic 3D spheroids as a model for steatosis and insulin resistance. Sci Rep, 2018, 8(1): 14297.
|
24. |
Bessone F, Razori M V, Roma M G. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci, 2019, 76(1): 99-128.
|
25. |
Kostrzewski T, Cornforth T, Snow S A, et al. Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease. World J Gastroenterol, 2017, 23(2): 204-215.
|
26. |
Suurmond C-a E, Lasli S, van den Dolder F W, et al. In vitro human liver model of nonalcoholic steatohepatitis by coculturing hepatocytes, endothelial cells, and kupffer cells. Adv Healthc Mater, 2019, 8(24): e1901379.
|
27. |
Magee N, Zou A, Zhang Y X. Pathogenesis of nonalcoholic steatohepatitis: interactions between liver parenchymal and nonparenchymal cells. Biomed Res Int, 2016: 5170402.
|
28. |
Hall Z, Bond N J, Ashmore T, et al. Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease. Hepatology, 2017, 65(4): 1165-1180.
|
29. |
Bulutoglu B, Rey-Bedón C, Kang Y, et al. A microfluidic patterned model of non-alcoholic fatty liver disease: applications to disease progression and zonation. Lab Chip, 2019, 19(18): 3022-3031.
|
30. |
Jang K J, Otieno M, Ronxhi J, et al. Reproducing human and cross-species drug toxicities using a liver-chip. Sci Transl Med, 2019, 11(517): eaax5516.
|
31. |
Nguyen D G, Funk J, Robbins J B, et al. Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. PLoS One, 2016, 11(7): e0158674.
|
32. |
Mukherjee S, Zhelnin L, Sanfiz A, et al. Development and validation of an in vitro 3D model of NASH with severe fibrotic phenotype. Am J Transl Res, 2019, 11(3): 1531-1540.
|
33. |
Underhill G H, Khetani S R. Emerging trends in modeling human liver disease in vitro. APL Bioeng, 2019, 3(4): 040902.
|
34. |
Andrade R J, Chalasani N, Björnsson E S, et al. Drug-induced liver injury. Nat Rev Dis Primers, 2019, 5(1): 58.
|
35. |
Zhou Y T, Shen J X, Lauschke V M. Comprehensive evaluation of organotypic and microphysiological liver models for prediction of drug-induced liver injury. Front Pharmacol, 2019, 10: 1093.
|
36. |
Fey S J, Wrzesinski K. Determination of drug toxicity using 3D spheroids constructed from an immortal human hepatocyte cell line. Toxicological Sciences, 2012, 127(2): 403-411.
|
37. |
Ewart L, Dehne E M, Fabre K, et al. Application of microphysiological systems to enhance safety assessment in drug discovery. Annu Rev Pharmacol Toxicol, 2018, 58: 65-82.
|
38. |
Kuna L, Bozic I, Kizivat T, et al. Models of drug induced liver injury (Dili) - current issues and future perspectives. Curr Drug Metab, 2018, 19(10): 830-838.
|
39. |
Ware B R, Durham M J, Monckton C P, et al. A cell culture platform to maintain long-term phenotype of primary human hepatocytes and endothelial cells. Cell Mol Gastroenterol Hepatol, 2018, 5(3): 187-207.
|
40. |
Rizki-Safitri A, Shinohara M, Tanaka M, et al. Tubular bile duct structure mimicking bile duct morphogenesis for prospective in vitro liver metabolite recovery. J Biol Eng, 2020, 14(1): 11.
|
41. |
Baze A, Parmentier C, Hendriks D, et al. Three-Dimensional spheroid primary human hepatocytes in monoculture and coculture with nonparenchymal cells. Tissue Eng Part C Methods, 2018, 24(9): 534-545.
|
42. |
Corbett J L, Duncan S A. iPSC-Derived hepatocytes as a platform for disease modeling and drug discovery. Front Med (Lausanne), 2019, 6: 265.
|
43. |
Ott L M, Ramachandran K, Stehno-Bittel L. An automated multiplexed hepatotoxicity and CYP induction assay using HepaRG cells in 2D and 3D. SLAS Discov, 2017, 22(5): 614-625.
|
44. |
Kizawa H, Nagao E, Shimamura M, et al. Scaffold-free 3D bio-printed human liver tissue stably maintains metabolic functions useful for drug discovery. Biochem Biophys Rep, 2017, 10: 186-191.
|
45. |
Gural N, Mancio-Silva L, HE J, et al. Engineered livers for infectious diseases. Cell Mol Gastroenterol Hepatol, 2018, 5(2): 131-144.
|
46. |
Li M, Wang Z Q, Zhang L, et al. Burden of cirrhosis and other chronic liver diseases caused by specific etiologies in China, 1990-2016: findings from the global burden of disease study 2016. Biomed Environ Sci: BES, 2020, 33(1): 1-10.
|
47. |
Paran N, Geiger B, Shaul Y. HBV infection of cell culture: evidence for multivalent and cooperative attachment. EMBO J, 2001, 20(16): 4443-4453.
|
48. |
Xia Y, Carpentier A, Cheng X, et al. Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions. J Hepatol, 2017, 66(3): 494-503.
|
49. |
Shlomai A, Schwartz R E, Ramanan V, et al. Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. Proc Natl Acad Sci U S A, 2014, 111(33): 12193-12198.
|
50. |
March S, Ramanan V, Trehan K, et al. Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens. Nat Protoc, 2015, 10(12): 2027-2053.
|
51. |
Ortega-Prieto A M, Skelton J K, Wai S N, et al. 3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection. Nat Commun, 2018, 9(1): 682.
|
52. |
World Health Organization. World malaria report 2016. Geneva Switzerland Who, 2016, 30(1): 189-206.
|
53. |
Gural N, Mancio-Silva L, Miller A B, et al. In vitro culture, drug sensitivity, and transcriptome of plasmodium vivax hypnozoites. Cell Host Microbe, 2018, 23(3): 395-406.
|
54. |
Talman A M, Blagborough A M, Sinden R E. A plasmodium falciparum strain expressing GFP throughout the parasite's life-cycle. PLoS One, 2010, 5(2): e9156.
|
55. |
Bao C Y, Hung H C, Chen Y W, et al. Requirement of cyclin-dependent kinase function for hepatitis B virus cccDNA synthesis as measured by digital PCR. Ann Hepatol, 2020, 19(3): 280-286.
|